Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Not yet recruiting, industry sponsors, Pain and anesthesia, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed755
14 trials
Showing 1 to 14, recently updated first.
- A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar ExtractionPivotal-lookingNot yet recruiting
South Rampart Pharma, Inc.Industry
NCT07945431 · 130 participants (planned) · Start Nov 30, 2026 · Primary completion Feb 28, 2027
Drug: SRP-001; Matching Placebo for SRP-001 · For: Acute Pain; Postoperative Pain; Pain and 1 more
Sites: Salt Lake City, Utah
- PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine CorrelatesNot yet recruiting
Antev Ltd.Industry
NCT07914062 · 84 participants (planned) · Start Feb 2027 · Primary completion Dec 2029
Drug: Teverelix DP; Teverelix DP and 2 more · For: Endometriosis Pelvic; Endometriosis Ovaries; Premenopausal and 3 more
- Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee OsteoarthritisPivotal-lookingNot yet recruiting
Genascence CorporationIndustry
NCT07831577 · 240 participants (planned) · Start Jul 2027 · Primary completion Oct 2029
Drug: Gene Therapy GNSC-001; Placebo · For: Knee Arthritis Osteoarthritis; Knee Arthritis, Osteoarthritis; Knee Arthritis and 6 more
- A Clinical Trial of GRT7040 in Adults With Acute Pain Following BunionectomyPivotal-lookingNot yet recruiting
Grünenthal GmbHIndustry
NCT07807644 · 400 participants (planned) · Start Sep 2026 · Primary completion Sep 2027
Drug: GRT7040; Hydrocodone bitartrate/ acetaminophen (HB/APAP) and 2 more · For: Acute Pain; Bunionectomy
- A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruiting
Glycyx TherapeuticsIndustry
NCT07662720 · 18 participants (planned) · Start Jul 15, 2026 · Primary completion Aug 31, 2027
Drug: axelopran; Pembolizumab · For: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Intradiscal rhGDF-6 for the Treatment of Lumbar Disc DegenerationNot yet recruiting
Cartago Biotech Pty LtdIndustry
NCT07668466 · 60 participants (planned) · Start Jul 4, 2026 · Primary completion Aug 31, 2028
Drug: High Dose; Low Dose · For: Disc Degenerative Disease; Back Pain
Sites: Kogarah, Australia
- A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular BlockadeNot yet recruiting
Amckaus PTY LTD.Industry
NCT07595393 · 64 participants (planned) · Start Aug 1, 2026 · Primary completion Jun 30, 2027
Drug: Rocuronium (0.6mg/kg); vecuronium bromide (0.1mg/kg) · For: Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery; Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery
- A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07551739 · 200 participants (planned) · Start Apr 2026 · Primary completion Nov 2026
Drug: HSK55718 dose level 1; HSK55718 dose level 2 and 3 more · For: Pain After Surgery
- The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee OsteoarthritisNot yet recruiting
TricelX Inc.Industry
NCT07487766 · 75 participants (planned) · Start May 2026 · Primary completion May 2027
Drug: Mesenchymal Stem Cell Injection · For: Osteoarthritis
Sites: Frisco, Texas
- Long Duration High Frequency Ultrasound for the Treatment of OsteoarthritisPivotal-lookingNot yet recruiting
ZetrOZ, Inc.Industry
NCT07515872 · 240 participants (planned) · Start May 1, 2026 · Primary completion May 31, 2027
Drug: Intra articular injection · For: Arthritis; Osteo Arthritis of the Knee
Sites: Stamford, Connecticut; Dryden, New York
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer PainPivotal-lookingNot yet recruiting
3D MedicinesIndustry
NCT05265052 · 177 participants (planned) · Start Dec 2026 · Primary completion Dec 2026
Drug: 3D1002 (50 mg)(Phase IIa); 3D1002 (100 mg)(Phase IIa) and 4 more · For: Cancer Pain
- Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic PainPivotal-lookingNot yet recruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07159243 · 180 participants (planned) · Start Sep 2025 · Primary completion Oct 2026
Drug: HL-1186; HL-1186 and 1 more · For: Diabetic Peripheral Neuropathic Pain
- Safety and Efficacy Study on AFA-281 for the Treatment of Low Back PainPivotal-lookingNot yet recruiting
Afasci IncIndustry
NCT06649747 · 408 participants (planned) · Start Apr 1, 2027 · Primary completion Mar 31, 2032
Drug: AFA-281 · For: Lumbosacral Radiculopathy
- A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use DisorderNot yet recruiting
Afasci IncIndustry
NCT06710431 · 36 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 1, 2027
Drug: AFA-281 · For: Alcohol Abuse; Alcohol Abuse/addiction; Anxiety and 3 more
Sites: Los Angeles, California
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.